Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579340 | 0.88 | ALDH1A1 (0.62) | KDM4EALDH1A1KMT2ABACE1MAPT | |
| SCHEMBL14617053 | 0.79 | MAPT (0.57) | KDM4EALDH1A1KMT2AMAPTNPSR1 | |
| SCHEMBL6904519 | 0.79 | ALDH1A1 (0.49) | KDM4EALDH1A1KMT2AMAPTNPSR1 | |
| SCHEMBL1767710 | 0.79 | ALDH1A1 (0.49) | KDM4EALDH1A1KMT2ABACE1MAPT | |
| SCHEMBL1884436 | 0.79 | ALDH1A1 (0.51) | KDM4EALDH1A1KMT2AMAPTNPSR1 | |
| SCHEMBL15358944 | 0.78 | MAPT (0.41) | KMT2ABACE1MAPTNPSR1LMNA | |
| SCHEMBL13356469 | 0.78 | MAPT (0.49) | ALDH1A1KMT2ABACE1MAPTALOX5 | |
| SCHEMBL4441765 | 0.77 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2ABACE1MAPT | |
| SCHEMBL28827445 | 0.77 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2ATSHRMAPT | |
| SCHEMBL120913 | 0.77 | KMT2A (0.70) | KDM4EALDH1A1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957112-B | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-114957112-A | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2022-08-30 | — | — | CN | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | KDM4E 2230/4885ALDH1A1 4276/4885KMT2A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.